MIL62 is a glycoengineered type II anti-CD20 monoclonal antibody with an Fc region N-glycan that is almost entirely afucosylated. It exhibits increased affinity for the FcgammaRIIIa receptor and possesses direct B-cell killing effects. MIL62 displays antibody-dependent cell-mediated cytotoxicity (ADCC) and is applicable for research in non-Hodgkins lymphoma (NHL).
Target:
Immunology/Inflammation related
* VAT and and shipping costs not included. Errors and price changes excepted
